{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-067901","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.304144+00:00","generated_at":"2026-05-24T01:54:11.910633+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL","bullets":["VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.","Mid dose (2.2mcg) met non-inferiority criteria on seroconversion for 20 of 24 serotypes; dose-dependent responses with little carrier suppression.","Four VAX-24-unique serotypes met all target criteria at all doses evaluated.","Company selects mid dose for optimized formulation; plans infant Phase 3 with VAX-24 or VAX-31 pending VAX-31 data (mid-2026).","Announces VAX-XL, third-generation PCV candidate designed to provide broadest coverage PCV in development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-067901","json":"https://secwatch.observer/filing/0001193125-25-067901.json","markdown":"https://secwatch.observer/filing/0001193125-25-067901.md","text":"https://secwatch.observer/filing/0001193125-25-067901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/0001193125-25-067901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:54:11.910633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}